Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inlexisertib + sotorasib
- Development stage
- Unknown
- Lead developer
- Deciphera Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy of **inlexisertib** (DCC-3116), an investigational selective autophagy inhibitor, and **sotorasib** (AMG 510, marketed as Lumakras), an FDA-approved selective KRAS G12C inhibitor. This combination is being studied for its safety and efficacy in patients with non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation. Inlexisertib targets and inhibits the ULK1/2 kinases, suppressing autophagy, which may enhance tumor cell death. Sotorasib binds irreversibly to KRAS G12C, inhibiting its oncogenic signaling. The combination aims to overcome acquired resistance to sotorasib by targeting parallel resistance pathways[3][5].
- Other names
- inlexisertib + sotorasib
02
Targets
ULK2 (Unc-51-like kinase 2)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on inlexisertib + sotorasib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inlexisertib + sotorasib.